Colchicine (Colcrys): Uses, Warnings, and Safety

What is colchicine?

Colchicine is an active ingredient used for the treatment of gout and familial Mediterranean fever (also called periodic illness in the source content).

In the United States, brand names listed in the source content include Colcrys, Mitigare, and Gloperba.

How colchicine works

Colchicine helps reduce the inflammatory response that follows the deposition of urate crystals in the joints. The source content describes effects on leukocyte movement, phagocytosis of urate microcrystals, and the inflammatory environment that contributes to crystal precipitation.

In simple terms, it is used to help calm the inflammation linked with gout attacks and related conditions.

Therapeutic uses and dosage information

The source content provides oral dosing examples for adults and children, but exact dosing must be checked in the official leaflet and with a healthcare professional, especially because colchicine can be toxic if used incorrectly.

Adults

• Acute gout attack: the source content describes a dose taken at the first sign of an attack, with a possible second dose 1 to 2 hours later if pain is not relieved.
• Prevention of gout attacks during initial therapy with allopurinol or uricosurics: the source content lists daily preventive use.
• Familial Mediterranean fever / periodic illness: the source content lists daily use in divided or single doses.
• Chronic gout: the source content lists daily use.

Children and adolescents under 18 years

The source content states that there are not enough data to establish recommendations for some gout uses in this age group. For familial Mediterranean fever, it lists age-based dosing ranges. These should be verified carefully with the official product information and a clinician.

Kidney function and dose adjustment

The source content notes that moderate renal insufficiency may require dose reduction and/or longer intervals between doses.

Contraindications listed in the source content

• Hypersensitivity to colchicine
• Pregnancy
• Severe renal failure and hemodialysis patients
• Severe liver failure
• Severe gastrointestinal disorders
• Stomach ulcer
• Cardiac disorders
• Blood dyscrasias or other hematological alterations
• Use within 14 days after CYP3A4 and/or P-glycoprotein inhibitors, as listed in the source content

Warnings and precautions

• Kidney failure and liver failure may require dose adjustment.
• Older adults, children, weakened patients, and people with alcohol misuse may have a higher risk of cumulative toxicity.
• Diarrhea may require dose reduction or stopping treatment under medical guidance.
• Blood problems such as leukopenia, thrombocytopenia, pancytopenia, aplastic anemia, and myelosuppression are listed in the source content; periodic blood tests may be needed.
• Neuromuscular toxicity and rhabdomyolysis are listed, with higher risk in older adults and people with renal insufficiency.
• Grapefruit juice should be avoided.
• The source content emphasizes a narrow therapeutic margin and the risk of fatal overdose.
• During treatment of an acute gout attack, monitoring for renal or hepatobiliary insufficiency is noted in the source content.
• Concomitant use with certain statins, fibrates, digoxin, or cyclosporine may increase the risk of myopathy.

Liver and kidney considerations

Liver failure

The source content states that colchicine is contraindicated in severe liver failure. It also notes caution in hepatic insufficiency, with close monitoring and dose reduction.

Kidney failure

The source content states that colchicine is contraindicated in severe renal failure. For moderate renal insufficiency, it notes dose reduction and/or longer intervals between doses.

Drug and food interactions

Colchicine has important interactions, especially with medicines that affect CYP3A4 or P-glycoprotein. The source content highlights the need for extra caution with these combinations.

• Possible myopathy risk: atorvastatin, simvastatin, pravastatin, fluvastatin, gemfibrozil, fenofibrate, fenofibric acid, bezafibrate, digoxin, cyclosporine
• Increased toxicity: clarithromycin, erythromycin, telithromycin, itraconazole, ketoconazole, indinavir, nelfinavir, ritonavir, saquinavir, grapefruit juice
• Increased serum concentrations: azithromycin
• Reduced absorption: vitamin B12

Pregnancy and breastfeeding

The source content lists pregnancy as contraindicated.

It also states that colchicine is excreted in breast milk and should not be administered during lactation.

Effects on driving and machines

The source content says colchicine has not been described as affecting the ability to drive vehicles or use machines.

Possible adverse reactions

The source content lists the following adverse reactions:

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Hepatic toxicity, identified after pharmacovigilance review

What to verify with a doctor or pharmacist

If colchicine is prescribed or already being used, it is important to confirm the following in the official leaflet or with a healthcare professional:

• The exact indication being treated
• The correct dose and schedule
• Whether kidney or liver function changes the dose
• Whether any current medicines may interact
• Whether grapefruit juice or other foods should be avoided
• What symptoms should prompt urgent medical attention

FAQs about colchicine

Sources and reference points

The source content states that the information was written using clinical and molecular information from medicines authorized and marketed in the United States under the UNII system, and it recommends checking the FDA medication guide for the specific product.

Useful reference points from the source content include FDA medication guides, UNII records, ChemIDplus, DrugPortal, PubChem, and NCI Thesaurus.